| ●Editorial | Uchida E | 294-5 |
| ●Drug development and Medical Research Act in the Netherlands | 297-388 | |
| ● Clinical Research: Policies and Practices in the Netherlands | Organized and sponsored by the Royal Netherlands Embassy |
297 |
| Welcoming remarks | Hamer A | 299 |
| Keynote speech: Innovations for clinical research | Kurokawa K | 300-5 |
| Policies and Public Private Partnership initiatives for clinical research | Stroeks R | 306-9 |
| Clinical research and innovation in the Netherlands | Aken PV | 310-9 |
| Climate for innovative drug research in the Netherlands | Henning RH | 320-33 |
| High tech early phase drug research in the Netherlands | Cohen A | 334-41 |
| Advances in late phase drug development | Grobbee DE | 342-52 |
| R&D base in the Netherlands - Big contribution to global R&D in Astellas | Tamura T | 353-58 |
| Q&A / Discussion | Moderator: Bleeker T | 359-65 |
| ● Article and translation | ||
| Explanatory review on ethical review system in the Netherlands | Uchida E，Kurihara C | 367-74 |
| Wet van 26 februari 1998, houdende regelen inzake medischwetenschappelijk onderzoek met mensen （Wet medischwetenschappelijk onderzoek met mensen） |
（trans. by Uchida E， Kurihara C） |
375-88 |
| ●The 26th Aso-Kuju Conference on Clinical Pharmacology The Present Conditions and Problems of the Institutional Review Boards（IRBs） | Chairman：Sasaguri T， Ohashi K，Nomoto M，Higuchi S | 389-455 |
| Introduction | Sasaguri T | 390-1 |
| Questionnaire survey on the institutional review boards in Fukuoka aiming
at the construction of the board member education system |
Sasaguri T，Shibata T， Ueguchi M，et al． |
393-419 |
| The activities of IRBs organized in the JACIC member facilities for phase I clinical studies | Iijima H，Momma T，Fukazawa I， et al． |
421-32 |
| Japan Association of Site Management Organizations（JASMO） Institutional Review Board（IRB）survey ─ Preliminary results and discussion─ |
Matsushima M，Kobayashi T， Iwakami K，et al． |
433-45 |
| Institutional reviews for clinical trials led by the independent physician | Nomoto M | 447-51 |
| Learning from the IRB workshop | Inano A | 453 |
| Education of IRB members | Ohashi K | 455 |
| ●Articles | ||
| Sales cancellation of Hydrochlorothiazide in Japan | Kuwajima I | 457-66 |
| Criticism on the Beers Criteria Japanese version：Premature consensus guideline | Saio T | 467-72 |
| ●Historical testimony series No.1：Drug Disaster SMON - How the company behave then? | ||
| Unrevealed and unsolved aspects of SMON in Japan | Suzuki S | 473-81 |
| Chronicle of Quinoform and the SMON disaster | Yamazaki T | 483-508 |
| Reflections on SMON：Press conference in Geneva and patients demonstration march in Basel | Beppu H | 509-13 |
| ●Manual for diagnosis of Adverse Drug Event | Shimizu N | 515-70 |
| ●Forum | ||
| You have got the tools and now you have to use them in a responsible way | Itoh K | 571-4 |
| ●Instructions for authors [Japanese] & [English] | 575-80 | |
| ●Editor's note | Kurihara M | 581 |